GlassScriptPhysician profile
Dana Yeske
NPI 1972963189
$2,700.05
in general payments reported to CMS, 2019-2025
25 companies · $819 in 2025
The $819 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $848 · 2024: $1,033 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.08 |
| Education | $219.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $822.10 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $254.29 | 2023-2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $191.58 | 2023-2025 | Calquence |
| Incyte Corporation | $176.84 | 2023-2025 | Monjuvi, Niktimvo, Jakafi |
| Merck Sharp & Dohme LLC | $169.91 | 2023-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $159.06 | 2023 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $155.87 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.05 | 2023 | Reblozyl |
| Genmab U.S., INC. | $120.92 | 2025 | Epkinly |
| Eisai INC. | $59.95 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $54.99 | 2025 | Onivyde |
| Beigene USA, INC. | $53.85 | 2024 | Tevimbra |
| Daiichi Sankyo INC. | $50.55 | 2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $35.05 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.24 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.80 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $30.80 | 2025 | Ninlaro |
| Emd Serono, INC. | $28.37 | 2025 | |
| Pfizer INC. | $26.59 | 2025 | |
| Genentech USA, INC. | $26.33 | 2024 | Columvi, Polivy, Lunsumio |
| Beone Medicines USA, INC. | $24.40 | 2025 | Tevimbra |
| Morphosys, US INC. | $21.90 | 2023 | Monjuvi |
| Btg International INC. | $17.62 | 2023 | |
| Caris Mpi, INC. | $17.33 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $13.66 | 2023 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Yeske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.